Stockscreener 앱 받기
2.05
3.54%
0.07
시간 외 거래:
2.06
0.01
+0.49%
전일 마감가:
$1.98
열려 있는:
$1.96
하루 거래량:
4.60M
Relative Volume:
0.58
시가총액:
$707.57M
수익:
$22,000
순이익/손실:
$-173.76M
주가수익비율:
-2.6689
EPS:
-0.7681
순현금흐름:
$-109.53M
1주 성능:
+1.99%
1개월 성능:
+10.81%
6개월 성능:
+13.89%
1년 성능:
+91.59%
1일 변동 폭
$1.92
$2.08
1주일 범위
$1.92
$2.19
52주 변동 폭
$1.03
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.05 | 714.47M | 22,000 | -173.76M | -109.53M | -0.7681 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2026-04-10 | 재개 | Jefferies | Buy |
| 2026-01-09 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-05-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes - Stock Titan
Allogene Therapeutics (ALLO) Income Statement & Earnings - moomoo.com
Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy - CRISPR Medicine News
State Street Corp Expands Allogene Therapeutics (ALLO) Stake with Strategic Share Purchase - GuruFocus
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs - The Globe and Mail
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $9 to $14 - moomoo.com
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - moomoo.com
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says - marketscreener.com
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - moomoo.com
Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
722,928 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Hennion & Walsh Asset Management Inc. - marketbeat.com
Allogene Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ... - Yahoo Finance
Allogene Therapeutics Inc (ALLO) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Allogene Therapeutics (ALLO) Advances Clinical Pipeline Amidst H - GuruFocus
Allogene Therapeutics: Q2 Earnings Snapshot - AOL.com
Allogene Therapeutics Q2 2026: EPS beats, cash extends to 2029 - scanx.trade
Transcript : Allogene Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Allogene Therapeutics Announces Q2 2026 Financial Results Highlighting Reduced Losses, First Collaboration Revenue, and Significant Equity Raise - Kalkine Media
Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast By Investing.com - Investing.com Canada
Allogene Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Allogene Therapeutics Q2 Earnings Call Highlights - marketbeat.com
Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast - Investing.com
Allogene TherapeuticsMay Offer Up To $500 Million In Securities - TradingView
Allogene Therapeutics Q2 Loss Narrows - marketscreener.com
Allogene Therapeutics (NASDAQ:ALLO) Issues Earnings Results, Beats Estimates By $0.04 EPS - marketbeat.com
Earnings Flash (ALLO) Allogene Therapeutics Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.17 Loss - marketscreener.com
Allogene posts $42.7 million Q2 loss as cash reaches $423.6 million - Quiver Quantitative
Allogene Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ALLO: ALPHA3 interim results highlight cema-cel's promise in LBCL and strong financial runway - TradingView
Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL - marketscreener.com
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update - GlobeNewswire
Allogene Therapeutics Inc (ALLO) Q2 2026 Earnings Report Preview: What To Look For - Yahoo Finance
Allogene Therapeutics (ALLO) Short Interest & Short Float | Updated Aug 2026 $ALLO - marketbeat.com
Allogene Therapeutics, Inc. expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Allogene Therapeutics (ALLO) stake: Belldegrun group reports 3.9% ownership - Stock Titan
State Street Corporation (ALLO) discloses 5.5% beneficial stake in Allogene - Stock Titan
Allogene Therapeutics (ALLO) Institutional Ownership 2026 $ALLO - MarketBeat
Allogene Therapeutics, Inc. (ALLO) Options Chain - Yahoo Finance
Allogene Therapeutics (ALLO) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
William Blair Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - Moomoo
Allogene Therapeutics Q2 Results: Earnings Call Set for Aug 12 - scanx.trade
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update - The Manila Times
Allogene sets Aug. 12 update on cancer and autoimmune disease - Stock Titan
Analysts’ Top Healthcare Picks: Repligen (RGEN), Allogene Therapeutics (ALLO) - The Globe and Mail
$Allogene Therapeutics (ALLO.US)$ Praise be to God - Moomoo
Allogene Therapeutics (ALLO) Stock Gains on FDA RMAT and Fast Tr - GuruFocus
Allogene Therapeutics stock rises on FDA regulatory designations By Investing.com - Investing.com South Africa
Allogene Therapeutics (ALLO) Gains FDA RMAT and Fast Track Desig - GuruFocus
Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma - marketscreener.com
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):